IXHL - Incannex Healthcare skyrockets amid trading halts
The value of recently-IPO’ed cannabinoid drug developer, Incannex Healthcare (IXHL +400.4%) have multiplied in morning hours Monday on above average volume. More than 147.2K Incannex (NASDAQ:IXHL) ADRs have traded so far, compared to the 65-day average volume of ~4.5K ADRs. The sudden surge in investor enthusiasm on the stock has already triggered several trading halts driven by volatility. Incannex (IXHL) focused on R&D and sale of medicinal cannabinoid products in Australia made its public debut in February. Last week, the company announced the completion of an early analysis in its phase 2 trial for cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea ('OSA').
For further details see:
Incannex Healthcare skyrockets amid trading halts